Apoptotic Pathway Manipulation

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages S1818-S1819

  Camidge, D Ross ^a   Thorburn, Andrew M ^b  

^a Medical Oncology   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84857089758     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000407571.60325.8c     Document Type: Article

References (13)

1. Call, JA, Eckhardt, SG, Camidge, DR, Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 9 (2008), 1002–1011.
2. Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
3. Mannhold, R, Fulda, S, Carosati, E, IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 15 (2010), 210–219.
4. Wu, H, Tschopp, J, Lin, SC, Smac mimetics and TNFalpha: a dangerous liaison?. Cell 131 (2007), 655–658.
5. Varfolomeev, E, Alicke, B, Elliott, JM, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 284 (2009), 34553–34560.
6. Tolcher, AW, Mita, A, Lewis, LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26 (2008), 5198–5203.
7. Talbot, DC, Ranson, M, Davies, J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 16 (2010), 6150–6158.
8. Hann, CL, Daniel, VC, Sugar, EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68 (2008), 2321–2328.
9. Gandhi, L, Camidge, DR, Ribeiro de Oliveira, M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29 (2011), 909–916.
10. Herbst, RS, Kurzrock, R, Hong, DS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16 (2010), 5883–5891.
11. Blackhall, FH, Márk, Z, Zatloukal, P, et al. A randomized phase II study of paclitaxel and carboplatin ± bevacizumab ± dulanermin in non-small cell lung cancer. J Clin Oncol, 28, 2010, 15s (Suppl; abstract 7534).
12. Von Pawel, J, Harvey, JH, Spigel, DR, et al. A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. J Clin Oncol, 28, 2010, 18s (Suppl; abstract LBA7501).
13. Karapetis, CS, Clingan, PR, Leighl, NB, et al. Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer. J Clin Oncol, 28, 2010, 15s (Suppl; abstract 7535).